Most Popular Reagents
Instruments
Antibodies
ELISA Kits
Protein Electrophoresis and Blotting
Protein and Antibody Purification
Recombinant Proteins
Molecular Biology
Stable Cell Lines
Cell Isolation and Activation
IVD Raw Materials
Therapy Applications
Resources
Expedite your drug development pipeline with screening solutions tailored for your screening needs, from simple unmodified design and preliminary screening, to complex modified design and functional analysis.
AI-Enhanced Sequence Design
Optimized design leveraging AI and experimental validation to increase knockdown efficiency and identify effective candidates.
Flexible, Diversified Packages
Candidate discovery, optimization, and bioanalysis services to meet your needs at any stage of therapy development.
Faster, One-Stop Service
Get efficient candidates in less time with design, synthesis, and screening in as fast as 6 weeks.
Starting at 6 weeks, $11K
Design, synthesis, and knockdown efficiency testing for naked siRNA/simple modified ASO*
Starting at 8 weeks, $22K
Design, synthesis, and knockdown efficiency and IC50 testing for naked siRNA/simple modified ASO*
Starting at 12 weeks, $38K
Design, synthesis, and knockdown efficiency and IC50 testing for modified siRNA/complex modified ASO*
All packages offer screening volumes of 20, 50, 100, or 200 sequences. Premium package starts at 50 sequences, recommend adding stability & off-target analysis.
* Simple modified ASO: Sequences designed with standardized Gapmer architectures (PS, MOE, OMe) with fixed modification patterns.
Complex modified ASO: Customized modifications available.
| Package Name | Service Content | Basic | Economy | Premium |
|---|---|---|---|---|
| Design & Synthesis | Naked siRNA/simple modified ASO | |||
|
Modified siRNA/complex modified ASO Predicts knockdown efficiency of modified siRNA |
||||
| In Vitro Screening (mRNA-level) |
Pilot experiment: detection plan confirmed for target gene | |||
| Round 1 screening (naked siRNA/simple modified ASO): screen all, single concentration | ||||
| Round 2 screening (naked siRNA/simple modified ASO): select 10 candidates for IC50 testing | ||||
| Round 3 &4 screening (modified siRNA/complex modified ASO): screen all, single concentration. Select 5 candidates for IC50 testing. | ||||
|
Optional | Optional | Optional | |
| Functional Assays |
|
Not applicable | Optional | Recommend |
| Deliverable | Design report: sequences, knockdown efficiency, off-target score, GC% content (modification plan for Premium package) | |||
| In vitro screening report: knockdown efficiency (IC50 for Economy & Premium package) | ||||
| Functional assay report: based on selected projects | Not applicable |
| Add-on Service | Service Content | Price |
|---|---|---|
| Patent search | Verify if candidate sequences are covered by existing patents and provide risk levels for client evaluation and selection for further development. | Additional evaluation fees required |
# Available cell line models for function testing >>
| Disease State or Tissue Type | Cell Line |
|---|---|
| Bladder cancer | RT-4 |
| Cervical cancer | Hela |
| Fibroblast cancer | SJCRH30 |
| Leukemia | THP1, Jurkat, SUP-T1 |
| Liver cancer | HepG2, Huh-7, Hep3B |
| Lung cancer | A549, H1975 |
| Neuroblastoma | SH-SY5Y, SK-N-BE(2) |
| Ovarian cancer | RMG-1 |
| Skin cancer | A375, A431 |
| Non-cancerous | HEK293T, HUVECS |
| Mouse | L929S, CHO, Raw264 |
| Primary cells | PBMC, Primary Cynomolgus Monkey Hepatocytes |
GenScript also support customized cell mode
Ready to order? Download the quote form and fill in the necessary information for your request. Send the quote form to your Technical Account Manager or to oligo@genscript.com.
Need help from an expert?
Genscript's Small Nucleic Acid Drug AI Design Platform
siRNA sequences designed for Gene B with GenScript's bioinformatic design platform achieved higher knockdown efficiency (KD%) than those created with other vendors' tools.
With GenScript's optimized design and superior synthesis capabilities, among the 50 designed siRNA, knockdown efficiency reached up to 91%, and 13 siRNA groups have knockdown efficiency higher than the positive control.
Among 150 designed ASO candidates, 9 ASOs achieves a knockdown efficiency of over 90%.
ELISA assay: suitable for quantification of secreted proteins
Qualitative as well as quantitative (Microplate reader)
Immunofluorescence Staining: suitable for quantification of membrane proteins
Qualitative as well as quantitative (Flow cytometry)
Western blot: suitable for quantification of all kinds of proteins
Qualitative, sometimes semi-quantitative (Gel electrophoresis)
siRNA Lipofection Protocol
Free Download
